Related Experiment Video
Updated: Jun 28, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Extensive-stage small-cell lung cancer: evolution of systemic therapy and future directions
Jeffrey Allen1, Mohammad Jahanzeb
1University of Tennessee Cancer Institute, Memphis, TN 38104, USA. jallen@utcancer.com
Abstract:
Extensive-stage small-cell lung cancer (ES-SCLC) is one of the most lethal malignancies, with a median overall survival of only 8-10 months with first-line chemotherapy despite response rates of 60%-80%. In the second-line setting, the prognosis is even more limited, with only 20%-30% of patients having a response and a median survival measured in weeks to months. This article will review systemic chemotherapy in first- and second-line treatment of patients with ES-SCLC and discuss novel therapeutic agents, cytotoxic and "targeted," with an emphasis on recently completed clinical trials and ongoing investigations.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Treatment Resistent Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
